Source: FinanzNachrichten

Virometix: Virometix Broadens Senior Leadership Team with Three Key Appointments

Virometix, a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases, to...

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Anna Sumeray's photo - CEO of Virometix

CEO

Anna Sumeray

CEO Approval Rating

90/100

Read more